There is a good chance that the next bit of news from Imugene is in regards to Azer-cel and FDA fast track designation.
It would of course depend upon the (DLBCL) disease meeting the requirements of this designation, i.e. unmet medical need and serious illness.
With the initial update of the OASIS trial data due in coming months, a good read is the presentation at the ASCO conference in June 2024.
Promising preclinical responses provided in this presentation.
https://imugene.com/wp-content/uploads/2024/11/ASCOTIPOASIS.pdf
DYOR opinion only
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $140.7K | 11.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 9000852 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 6923007 | 25 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |